(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 July 2014 (24.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/111841 A3

(51) **International Patent Classification**:
C07K 14/47 (2006.01)

(21) **International Application Number**:
PCT/IB2014/058234

(22) **International Filing Date**:
13 January 2014 (13.01.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
1300683.8 15 January 2013 (15.01.2013) GB

(71) **Applicants**: **APITOPE INTERNATIONAL NV** [BE/BE]; Campus Diepenbeek, Angoralaan, B-3590 Diepenbeek (BE). **MERCK SERONO S.A.** [CH/CH]; Centre Industriel, 1267 Coinsins (CH).

(72) **Inventors**: **WRAITH, David**; c/o School of Cellular and Molecular Medicine, University of Bristol, Medical Sciences Building, Bristol BS8 1TD (GB). **STREETER, Heather**; c/o School of Cellular and Molecular Medicine, University of Bristol, Medical Sciences Building, Bristol BS8 1TD (GB). **ORDONEZ, Laurence**; 7 allée Rémy Raymond, 31840 Seilh (FR).

(74) **Agent**: **HOLLIDAY, Louise**; D Young & Co LLP, 120 Holborn, London EC1N 2DY (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
30 October 2014

WO 2014/111841 A3

(54) **Title**: PEPTIDE

(57) **Abstract**: There is provided a peptide which is capable of binding to an MHC molecule *in vitro* and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises all or a portion of the following proteolipid protein (PLP) peptides: PLP 36-61: HE ALTGTEKLIET YF SKN YQD YEYLI (SEQ ID NO. 1) PLP 179-206: TWTTCQSIAFPSKTSASIGSLCA-DARMY (SEQ ID NO. 2) PLP 207-234: GVLPWNAFPGKVCGSNLLSICKTAEFQM (SEQ ID NO. 3). There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide.